glp-1 weight loss drug news november 2025 Weight-Loss Drugs Ride Health, Wellness Wave GLP-1 Weight Loss Drug Market

However, larger prospective randomized studies are needed to identify the optimal treatment strategies for post-bariatric weight regain, which is a frequent challenge in this growing population.

Losing weight is an important way to improve various aspects of your health

Unlike earlier GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) that target a single hormone pathway, or tirzepatide (Mounjaro/Zepbound) that targets two, retatrutide activates three distinct metabolic receptors : GIP, GLP-1, and glucagon

Research from the STEP trials (semaglutide) and SURMOUNT-4 (tirzepatide) shows that without ongoing pharmacotherapy or substantial behavioral interventions, significant weight regain occurs within the first year after stopping treatment

Identify how REG1A, GP2 biomarkers, and particular microRNAs may be useful for early diagnosis